Navigation Links
Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
Date:4/6/2011

MALIBU, Calif., April 6, 2011 /PRNewswire/ -- Cliffside Malibu, one of America's leading drug and alcohol treatment centers, is strongly urging its patients who are currently taking antidepressants not to stop, despite a new study and subsequent media reports that such drugs could raise the risk of heart attack or stroke in middle-age men taking the medications.  Cliffside is using e-mail, phone calls and face-to-face therapy sessions to encourage its patients who rely on those medications to continue doing so under close supervision by their psychiatrists.

"While the findings of this very preliminary study are interesting and should be taken seriously, we are strongly urging our patients to continue using antidepressants as prescribed," said Cliffside Malibu CEO Richard Taite.  "The immediate, serious risks to our patients were they to abruptly halt the use of antidepressants far outweigh potential adverse health effects."

A presentation at a cardiology conference earlier this week suggested antidepressants could lead to as much as a five percent increase in the thickness of the carotid artery.  The study's author, Dr. Amit Shah, has reportedly cautioned that the findings of the 513-person study are not enough to warrant taking patients off of antidepressants, and noted that depression elevates risk for heart disease.

"The symptoms of depression in our patients, many of whom suffer from mood and other disorders, are often acute and even life-threatening.  We are reaching out to every current and former patient to educate them and to ensure they make wise decisions in partnership with their physicians," added Taite.

About Cliffside Malibu

Cliffside Malibu is a full-service residential drug rehab and alcohol addiction treatment center in the Los Angeles area.  At C
'/>"/>

SOURCE Cliffside Malibu
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
4. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
5. Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution
6. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
7. First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
8. Two National Organizations Join DRIVE4COPD Movement to Raise Awareness of Nations Fourth Leading Cause of Death
9. PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry
10. DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort
11. Reportlinker Adds The 2011 Top Ten Worlds Leading Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... , Aug. 21, 2014 Nektar ... International Inc. today announced positive results from its ... an investigational, extended half-life recombinant factor VIII (rFVIII) ... Factor (Recombinant)], which met its primary endpoint in ... arm compared to the on-demand arm. ...
(Date:8/21/2014)... Canadian Epilepsy Alliance (CEA) is thrilled to announce the launch ... the most common neurological disorder in Canada ... tells a fictional story based on the experiences of 14-year-old ... "Despite the fact that epilepsy affects 1 ... lack of awareness out there," says Gail Dempsey , ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
(Date:8/22/2014)... LA The LSU Health New Orleans School ... Nursing Traineeship grant to increase access to advanced ... and under-represented groups, as well as veterans. The ... Department of Health and Human Services awarded the ... as the grant,s project director., The Advanced Education ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... oncogenic somatic mutation at amino acid 918 in the ... small cell lung cancer (SCLC) tumors and enforced expression ... intracellular signaling and cell growth. , SCLC is a ... all lung cancers and is strongly associated with tobacco ... extensively examined for genomic alterations and targeted therapies are ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... 28 WellSpring Pharmaceutical,Corporation, a growing North American-based ... named Chief Operating Officer.,Formerly, Ms. Shusko held the ... in early 2000. In her new role as ... her areas of oversight,to operations with an initial ...
... NQF-endorsed measures can improve quality of care for ... the,importance of quality healthcare for mothers and newborns ... measure and thereby,improve care received by mothers and ... discharge. Consensus standards improve quality,of care by standardizing ...
... who received blood that was 29 days or older faced ... Hospital patients who receive a transfusion of stored blood that ... developing one or more serious infections compared to those who ... pointed out that current U.S. regulations set the upper limit ...
... Device Designed to Minimize Discomfort and Pain Following ... a world-leading,manufacturer of ostomy and wound care products, ... a new post-operative ostomy,device. The product offers clinicians ... manage abdominal pain in the days and weeks ...
... Today, PARI Respiratory,Equipment presented a comparative study ... in-vitro performance and delivery,efficiency of budesonide inhalation ... study show that the LC Sprint,Reusable Nebulizer ... average,of 4.9 minutes, and had the highest ...
... of Portland,Oregon is pleased to announce its partnership ... a new company, Wellsource Health Solutions.,This joint venture ... provide,full-service solutions that meet the specific needs of ... Customers and their,participants will benefit from a new ...
Cached Medicine News:Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 3Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 2Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 3Health News:PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 3
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Ultraview 1700 Central Monitor...
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
Medicine Products: